Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

NEW YORK – In March, a new EU-funded project will commence that aims to deliver a series of new tests and tools for diagnosing urinary tract infections in low- and medium-income countries, especially ...

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

NEW YORK – Abbott has received 510(k) clearance from the US Food and Drug Administration for its cardiac function test intended to help diagnose heart failure. The Alere NT-proBNP assay for the ...

The test, which is intended for assessing cardiovascular risk, is the first lipoprotein (a), or Lp(a) test measured in nanomoles per liter to receive FDA clearance.